HC Wainwright & Co. Reiterates Buy on Foghorn Therapeutics, Lowers Price Target to $13
Benzinga Newsdesk 1 year ago
NewsPrice TargetReiterationAnalyst Ratings
HC Wainwright & Co. analyst Andrew Fein reiterates Foghorn Therapeutics (NASDAQ:FHTX) with a Buy and lowers the price target from $20 to $13.
HC Wainwright & Co. analyst Andrew Fein reiterates Foghorn Therapeutics (NASDAQ:FHTX) with a Buy and lowers the price target from $20 to $13.